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AbsTrACT
The favourable long- term results of early treatment 
in patients with classified rheumatoid arthritis have 
resulted in an increasing interest in the diseases phases 
preceding clinical arthritis. The hypothesis to test is that 
an intervention in these early phases may better prevent 
or reduce disease persistence than an intervention when 
arthritis has become clinically manifest. While several 
placebo- controlled trials are still ongoing, to date there 
is no firm evidence that this hypothesis truly holds. 
Therefore, it is important to reflect on the current status 
of arthralgia preceding clinical arthritis. Inherent to every 
new field of research, attitudes are conflicting, with 
opinions propagating innovation (based on the fear of 
undertreatment) on the one hand, and critical sounds 
pleading for more restraint (fear of overtreatment) on 
the other hand. In this Viewpoint, we will examine these 
divergent opinions, relate them to a preferred ultimate 
scenario and provide considerations for future studies 
and daily practice.
InTroduCTIon
Early treatment start has become the cornerstone 
of the management of early arthritis and rheuma-
toid arthritis (RA).1 2 This concept has resulted in 
an increasing interest in the period before swollen 
joints actually appear, with the underlying assump-
tion that disease processes that are still developing 
are more susceptible to permanent modification. 
Treatment success in the prearthritis phase will 
for instance be reflected by a lower incidence of 
persistent clinical arthritis, as disease persistence 
can hardly be affected anymore when treatment 
is initiated only when arthritis has appeared. 
Whether disease modifying anti- rheumatic drug 
(DMARD) treatment started in the prearthritis 
phase is truly more effective will become clear 
from the currently ongoing placebo- controlled 
proof- of- concept trials. Results will become avail-
able in the next 2 years.3–6
Therefore, it is important now to reflect on the 
status of the field of arthralgia preceding clinical 
arthritis. How should we deal with the tempta-
tions of scientific progress? Should we already try 
to positively influence the lives of current individ-
uals presenting with arthralgia, but still without 
arthritis? How will such a practice influence the 
chance that we will ever get real evidence- based 
treatments in this field that are beyond beliefs? 
In this Viewpoint, we will investigate these ques-
tions. We will search for a trade- off between opin-
ions propagating innovation on the one hand and 
critical sounds pleading for restraint on the other 
hand, conflicting opinions that are inherent to 
new fields of research.
THe dIlemmA
In the absence of evidence for the value of drug 
interventions in the phase preceding clinical 
arthritis, several scenarios may apply to describe the 
current thinking.
The first is the scenario of hope. To cite the 
American philosopher J. Dewey ‘every great 
advance in science has issued from a new audacity 
of imagination’. Treatment of RA has considerably 
improved and the hope is to further improve the 
lives of patients with RA, curing the disease or even 
prevent it. This hope is fuelled by promising results 
of DMARD- intervention in early RA. The contribu-
tion of timing of treatment to treatment success has 
driven researchers to study biological mechanisms 
that precede clinical arthritis. In clinical practice, 
patients with arthralgia suspicious of progression 
to RA, but yet without clinically apparent arthritis, 
are increasingly recognised. Until recently, these 
patients were sent home with the advice to come 
back in case of clinical arthritis. To date, some clini-
cians feel the need to start DMARD- therapy prior 
to the development of clinical arthritis, especially 
if laboratory or imaging findings suggest that RA 
is looming. They hope to add value to the lives 
of these patients and argue that—when ongoing 
trials will teach us that treatment in the prearthritis 
phase is effective—withholding DMARD- treatment 
would in hindsight mean undertreatment, a situa-
tion that they would rather avoid.
The second scenario is that of criticism or 
perhaps pessimism. The underlying sentiment is 
that, now disease activity can be so well suppressed 
in most RA patients, too early treatment may do 
more harm than good. In other words, very early 
treatment start could result in ‘overdiagnosis’ and 
overtreatment. In this view, the valuable progress 
that has been achieved has created a new problem. 
The British psychologist Havelock Ellis described it 
as follows: ‘What we call progress is the exchange 
of one nuisance for another nuisance’.
As so often, a third scenario that appropriately 
balances the risks of undertreatment and overtreat-
ment is likely the ideal scenario.
lookIng bACk
Balancing the risks of undertreatment and over-
treatment in RA is not new. Fifteen years ago, 
similar discussions pertained to patients with 
undifferentiated arthritis (UA), that is, patients 
with clinically evident arthritis that do not fulfil 
classification criteria for RA or other inflammatory 
arthritides. Initially, patients diagnosed with UA 
were not treated with DMARDs. Only after ample 
validation of models predicting the risks in indi-









is: first published as 10.1136/annrheum
dis-2019-216716 on 8 January 2020. Downloaded from
 
2 van der Helm- van Mil A, Landewé RBM. Ann Rheum Dis 2020;0:1–4. doi:10.1136/annrheumdis-2019-216716
Viewpoint
box 1 Considerations on treatment of patients with 
arthralgia suspicious for progression to rA
 ► There is no evidence that starting DMARD treatment in this 
disease phase is effective.
 ► Several proof- of- concept trials are currently ongoing.
 ► Subsequent trials require long- term follow- up to determine if 
outcomes (absence of clinical arthritis, absence of persistent 
arthritis, achieving DMARD- free status) are sustainable. 
These trials should include outcomes that reflect real value 
to patients, such as patient- reported symptoms, functional 
ability and workability.
 ► The EULAR definition of arthralgia suspicious for progression 
to RA confers a high sensitivity for RA development but 
only a moderate specificity. Adding information from other 
biomarkers is needed to further increase specificity.
 ► Currently, there is no validated risk stratification method to 
reliably estimate the risk of progressing to RA. Analyses on 
a combination of markers in relation to the natural disease 
course in all relevant longitudinal data- sets are needed to 
achieve this.
 ► In daily clinical practice, rheumatologists may wish to balance 
the risks of overtreatment and undertreatment in patients 
with arthralgia suspicious for progression to RA. However, 
absence of evidence on risk estimations and on efficacy 
currently favours a decision not to treat arthralgia with 
DMARDs in the absence of clinical arthritis. Furthermore, 
evaluation of the natural course will shed light on risks in the 
nearby future.
RA, rheumatoid arthritis.
notion occurred that UA should better be treated. Finally, in 
order to be able to also classify patients earlier in time, novel 
classification criteria for RA were developed.13 Intriguingly, all 
placebo- controlled randomised clinical trials in patients with 
UA were negative for their primary endpoint, the fulfilment of 
classification criteria for RA.14–18 These negative results may be 
explained by methodological limitations, such as small sample 
sizes and absence of risk stratification at inclusion. They may 
also indicate that—if prevention of RA is the ultimate goal—the 
phase of UA is too late to start DMARD- treatment. Posthoc 
analysis of a trial with methotrexate in the subgroup of patients 
with a high risk to progress to RA showed statistically signifi-
cant and clinically relevant effects.19 A meta- analysis of all trials 
performed in patients with UA provided similar results that 
were statistically significant.20 To what extent overtreatment 
or undertreatment exists in UA will forever remain unclear, 
because DMARD treatment of patients with UA is common 
practice now. In the absence of solid scientific evidence from 
clinical trials, treatment decisions are guided by clinical exper-
tise and personal experiences.
WHAT CAn We leArn from THe reCenT pAsT?
In light of the preferred third scenario, important learning points 
from the past 15 years include the need to conduct well- designed 
placebo- controlled clinical trials, the need to base our future 
actions on the results of these trials and to refrain from imple-
menting anticipated results in daily practice that are not (yet) 
existent.
Adequate trial design means requirements for statistical power, 
eligible patients, preferred outcome(s) and follow- up duration. 
Sufficient statistical power seems a trivial requirement but is 
tricky, because statistical power depends on the difficult to esti-
mate proportion of patients who will get the ultimate outcome 
(RA). The failure of previous clinical trials with either UA or 
arthralgia to meet their primary endpoint has been attributed to 
insufficient sample sizes.
Choosing the best primary outcome is also not straightfor-
ward. The primary outcome used so far was fulfilment of RA 
according to classification criteria. The question is whether this 
outcome best reflects added value to patients. Nowadays the 
involvement of patient partners in research has paid off and 
patients have indicated that current disease burden is mostly 
caused by pain, fatigue and functional impairments.21 From this 
perspective, added value may better be expressed as the possi-
bility to acquire symptom resolution and maintain a normal 
daily living (including work). There is also increasing pressure 
from society to spend healthcare resources more parsimo-
niously, especially in light of the risen drug expenses for RA. 
Furthermore, from a methodological perspective, the achieve-
ment of an outcome at a single point in time is not reflective of 
the subsequent disease course. More specifically, the occurrence 
of clinically apparent arthritis (or RA) at a single time point 
does not say anything about whether the disease will be self- 
limiting, whether remission will be rapidly achievable with first- 
line therapy, whether a DMARD- free status can be achieved 
over time or whether the disease will be persistently active or 
poorly responsive. Sustained DMARD- free remission may be a 
better outcome, as it includes a form of persistence in its defi-
nition.22 Altogether, a long- term follow- up of patients included 
in pre- RA trials is required to evaluate if results are sustainable 
and valuable, which is challenging as trials generally tend to 
shorten the follow- up duration. Considerations are summarised 
in box 1.
IdenTIfyIng persons WITH ArTHrAlgIA AT rIsk for rA
Defining the population of patients with arthralgia but without 
clinical arthritis, and who are supposedly at risk for RA, is 
another crucial element. The risk influences the required sample 
size: at a similar power, a larger sample is required if the risk for 
RA is low or moderate, as compared with a scenario in which the 
risk is high. Moreover, overtreatment becomes more of an issue 
if the actual proportion that will develop RA is smaller. Apart 
from accurate, the risk estimation should be robust and validated 
in data from different centres and countries. Since identifying 
RA purely based on underlying biological markers is still impos-
sible, a proper diagnosis must rely on a combination of features 
and pattern recognition. A combination of clinical symptoms 
and signs suggestive of future RA has been developed, resulting 
in the EULAR definition of arthralgia suspicious for progression 
to RA.23 The clinical definition has shown to be highly sensi-
tive when tested against the external standard ‘expert diagnosis 
of RA’ in cross- sectional studies and actual RA development in 
longitudinal studies.23 24 In order to obtain a sufficiently high 
specificity, the clinical definition should be combined with the 
results of biomarkers. Accumulating evidence suggest that auto- 
antibodies and imaging- detected subclinical inflammation are 
the most promising biomarkers. A non- systematic look in the 
literature yields several different prediction models that have 
been construed.25–29 Unfortunately, none of these has reported 
cross- validation in independent centres, which leaves researchers 
with residual uncertainty. Collaboration based on data sharing 
across centres and obtaining consensus on the preferred meth-
odology is needed to optimally define a population at high risk 
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AssessIng ACCurACy of IdenTIfyIng rIsk for rA
Risk estimators for groups of patients in trials differ principally 
from those for individuals in clinical practice. In individual 
patients, positive and negative predictive values, expressing the 
likelihoods of contracting a disease or remain free of that, are the 
pivotal estimates. Ideally, these should approach 100%. This is an 
almost impossible scenario in rheumatology. Diagnostic criteria 
that are intended to be used in individual patients are therefore no 
longer pursued by the professional organisations. Initially, prog-
nostic research has focused on the ability to identify patients at risk 
for RA: the sensitivity. However, as a high sensitivity harbours the 
risks of ‘overclassification’ and overtreatment, attention has shifted 
from high sensitivity to high specificity (or properly recognising 
the persons that will not develop RA). The best risk classification 
model therefore has a high accuracy based on high sensitivity and 
high specificity. Designing and validating such a model is a ‘hercu-
lean task’ since sensitivity and specificity tend to operate in oppo-
site directions. A factor that further complicates the matter is that 
even in the presence of a high specificity absolute likelihoods can 
still be low (Bayesian rule). A good example is the ACPA- test, with 
a documented specificity of 98%, that in populations with a low 
prior risk of RA, such as the general population, yields an individual 
likelihood of RA development of only 5%, corresponding to a like-
lihood of 95% of not getting RA.30 31 In more selected populations 
with higher prior risk, higher positive predictive values (PPVs) can 
be found.28 32 ‘The pre- RA period’ is a continuum that extends 
from health to the time immediately before the development of 
clinical arthritis and diagnosis or classification of RA. The risk of 
persistent disease varies by the place in this spectrum; risk strati-
fication algorithms should therefore be developed for subpopula-
tions separately.
ConsIderATIons oTHer THAn ACCurACy
It is arguable, though, whether trials on DMARD- treatment 
in at risk populations are only justified in the context of opti-
mally accurate prediction models. Whether overtreatment or 
undertreatment, due to suboptimal accuracy, will be consid-
ered socially acceptable depends on many factors such as the 
likelihood of harm (toxicity of treatment, psychological harm 
caused by uncertainty about getting ill), treatment expenses, and 
consequences of missing a diagnosis. Satisfactory answers can 
only be provided by international consensus about preferable 
risk stratification models, validation of such models in interna-
tional databases with data about the natural course and all levels 
of variability. An estimation of the added value for individuals 
should be part of discussion. These discussions that involve all 
stakeholders may ultimately lead to consensus on what is the 
best trade- off between ‘ideal’ and ‘feasible’. Importantly, persons 
at risk should be included in these discussions, as their beliefs 
and preferences will predict treatment uptake.33 Optimal partic-
ipation in this process requires that information is lucid, fair and 
comprehensible to lay- people.34
So far, we have focused on pharmacological interventions in 
selected populations, but we appreciate the relevance of generic 
lifestyle interventions such as smoking cessation. Such interven-
tions have a lower risk of harm than DMARDs and are also asso-
ciated with other positive public health effects.
WHAT does THe CurrenT sITuATIon Imply for pATIenTs 
WITH ArTHrAlgIA suspICIous for progressIon To rA 
In dAIly prACTICe?
Since there is no broadly accepted method to identify patients 
at risk for RA with sufficient precision, scenario three in which 
both undertreatment and overtreatment are minimised does not 
yet exist. As discussed in the previous paragraphs, long- term 
observational data on the natural course and outcome are crucial 
for achieving accurate prognostication. Evaluation of biosamples 
from longitudinal cohort studies may help elucidating mecha-
nisms that drive the progression from arthralgia to clinically 
evident RA and may reveal targets for potential intervention. 
Treating patients before they present with clinical arthritis will 
make it impossible to obtain reliable information about the 
natural course of the disease. We may then end up in the belief 
that we are treating the correct patients, but without appropriate 
scientific endorsement. This scenario bears resemblance to the 
current situation for patients with UA. For now, we should learn 
lessons from the past and remain reluctant to start treatment in 
the absence of clinical arthritis.
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